| Autor: |
Yang, Yang, Huang, Fengming, Qiao, Xiangyu, Chen, Sheng, Zhang, Cong, Deng, Xingyu, Gu, Wentao, Peng, Ling, Cao, Mengli, Jiang, Jingmei, Gao, George F., Liu, Yingxia, Jiang, Chengyu |
| Předmět: |
|
| Zdroj: |
IUBMB Life; Nov2024, Vol. 76 Issue 11, p960-971, 12p |
| Abstrakt: |
To date, SARS‐CoV‐2 has caused millions of deaths, but the choice of treatment is limited. We previously established a platform for identifying Food and Drug Administration (FDA)‐approved repurposed drugs for avian influenza A virus infections that could be used for coronavirus disease 2019 (COVID‐19) treatment. In this study, we analyzed blood samples from two cohorts of 63 COVID‐19 patients, including 19 patients with severe disease. Among the 39 FDA‐approved drugs we identified for COVID‐19 therapy in both cohorts, 23 drugs were confirmed by literature mining data, including 14 drugs already under COVID‐19 clinical trials and 9 drugs reported for COVID‐19 treatments, suggesting the remaining 16 FDA‐approved drugs may be candidates for COVID‐19 therapy. Additionally, we previously reported that herbal small RNAs (sRNAs) could be effective components in traditional Chinese medicine (TCM) for treating COVID‐19. Based on the abundance of sRNAs, we screened the 245 TCMs in the Bencao (herbal) sRNA Atlas that we had previously established, and we found that the top 12 TCMs for COVID‐19 treatment was consistent across both cohorts. We validated the efficiency of the top 30 sRNAs from each of the top 3 TCMs for COVID‐19 treatment in poly(I:C)‐stimulated human non‐small cell lung cancer cells (A549 cells). In conclusion, our study recommends potential COVID‐19 remedies using FDA‐approved repurposed drugs and herbal sRNAs from TCMs. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text